Key regions: Australia, Germany, United Kingdom, United States, France
The Immunosuppressants market in CIS has been experiencing steady growth in recent years.
Customer preferences: Patients in CIS countries suffering from autoimmune diseases and transplant recipients are the main consumers of immunosuppressants. The demand for these drugs is driven by the increasing prevalence of autoimmune diseases and organ transplants in the region. Patients in CIS countries prefer immunosuppressants that are effective, affordable, and have minimal side effects.
Trends in the market: The Immunosuppressants market in CIS is expected to grow due to the increasing prevalence of autoimmune diseases and organ transplants. The market is also driven by the availability of generic drugs, which are more affordable than branded drugs. The trend towards using combination therapies is also expected to drive growth in the market. In addition, the market is expected to benefit from the increasing use of biologics, which have proven to be effective in treating autoimmune diseases.
Local special circumstances: The healthcare infrastructure in some CIS countries is not well-developed, which limits access to healthcare services and drugs, including immunosuppressants. This has resulted in a large number of patients in the region going untreated. In addition, the market is highly regulated, which can make it difficult for new entrants to enter the market.
Underlying macroeconomic factors: The economic situation in CIS countries has a significant impact on the Immunosuppressants market. Economic growth in the region has been sluggish in recent years, which has limited the purchasing power of consumers. This has resulted in a preference for more affordable generic drugs. In addition, the political situation in some CIS countries can also impact the market, as changes in government policies can lead to changes in healthcare regulations and access to drugs.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
